What are oral anticoagulants used for?
Oral anticoagulants, also called vitamin K antagonists (VKAs), are used to prevent the occurrence or increase of unwanted blood clots. They inhibit enzymes called vitamin K epoxide reductase and vitamin K reductase. These enzymes are required for chemical reduction of oxidized vitamin K.
What does DOACs stand for?
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts.
What is a warfarin antagonist?
Warfarin is a vitamin K antagonist that is used as an oral anticoagulant agent in the prevention and treatment of thromboembolic disorders and embolic complications arising from atrial fibrillation or valve replacement.
Which drugs are anticoagulants?
What are anticoagulants?
- apixaban (Eliquis)
- dabigatran (Pradaxa)
- edoxaban (Lixiana)
- rivaroxaban (Xarelto)
- warfarin (Coumadin)
Which anticoagulant is best?
“Overall, apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin,” the authors write. “Rivaroxaban and low-dose apixaban were, however, associated with increased risks of all-cause mortality compared with warfarin.”
What are NOACs and DOACs?
Direct oral anticoagulants (DOACs) are oral medications that specifically inhibit factors IIa or Xa. They are also known as new oral anticoagulants (NOACs) or target-specific oral anticoagulants (TSOACs). DOACs are the preferred name according to the International Society of Thrombosis and Haemostasis [1].
Why is it called DOAC?
The term DOAC (pronounced ‘DOH-ack’) stands for ‘Direct Oral AntiCoagulant’ and refers to a group of new anticoagulant medications. An anticoagulant is a medica- tion that either treats or prevents blood clots, often called a ‘blood thinner’.
What are vitamin K antagonists used for?
Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial fibrillation (AF) and the treatment and secondary prevention of venous thromboembolism.
